Strategic partnerships Position Biosplice for collaboration with large pharma through co-development or exclusive license deals leveraging DYRK1A/CLK2 inhibitors and the unique LOR delivery profile for osteoarthritis, diabetes, oncology, and neurology programs.

Expansion opportunities Target potential tier-1 and tier-2 pharma companies seeking small-molecule pipelines in orthopedics, metabolic diseases and neuro-oncology; emphasize long-acting intra-articular approaches and first-in-class potential to accelerate diligence.

Clinical value highlights Highlight the program’s demonstrated improvements in pain, function, and medial joint space width with a favorable safety profile to attract out-licensing discussions and investor interest from BD teams evaluating risk-adjusted value.

Affiliates and adjuncts Leverage TenaRx and Roskamp Institute collaborations to broaden access points and demonstrate a robust ASN (affiliates, strategic collaborations, networks) narrative for multi-disease expansion and evidence generation.

Funding and milestones Use the substantial funding runway and recent partnerships (Novo Nordisk, Epic Sciences) to build credibility in deal conversations, outlining potential milestone-rich structures and co-development economics to attract partners.